Eli Lilly and Company LLY

LLY Company Overview

Eli Lilly and Company is a U.S.-based global pharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines across several therapeutic areas, including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular disease. The company operates within the biopharmaceutical industry and generates the majority of its revenue from prescription drug sales. Lilly’s largest revenue drivers in recent years have included diabetes and obesity treatments such as Mounjaro (tirzepatide), Zepbound, Trulicity, and oncology and immunology products including Verzenio and Taltz. The company serves healthcare providers, hospitals, pharmacies, governments, and patients across both developed and emerging markets.

Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, the company evolved from a regional pharmaceutical manufacturer into one of the world’s largest research-driven drug companies. Lilly has historically been associated with major pharmaceutical innovations, including early insulin commercialization and advancements in neuroscience and oncology therapies. Its strategic positioning has increasingly centered on metabolic disease leadership, large-scale biologics manufacturing capacity, and a broad late-stage clinical pipeline. Public disclosures in SEC filings, investor presentations, and major financial publications consistently identify obesity and diabetes therapeutics as central to Lilly’s current growth strategy.